posted on 2022-02-23, 21:19authored byLauren A. Johnson, Katy A. Marino, Jason L. Muesse
<p>Esophageal stents are useful for palliation of dysphagia in
patients who are not candidates for other therapy modalities either because of
their comorbidities or because of tumor characteristics that classify the
lesion as unresectable. Stenting is also indicated in patients with recurrent
disease after completion of primary treatment. Stents are also used in the
treatment of malignant tracheoesophageal fistulas as well as for nutritional
support during neoadjuvant therapy. Benign indications for use include patients
with esophageal perforations that are otherwise surgically unfit, patients with
anastomotic leak after esophagectomy, and in patients with refractory
esophageal strictures. Absolute contraindications include proximity of the
lesion to the upper esophageal sphincter, presence of tracheal stent, and
perforation measurement greater than 50 percent circumference of the esophagus
or greater than 5cm in length. Relative contraindications include
hemodynamically unstable patients as well as those with unresolved
coagulopathy. Proximity of the lesion to the gastroesophageal junction (GEJ) is
also a relative contraindication due to the risk of stent migration or stent
placement in the stomach. </p>
<p> </p>
<p>Self-expanding metal stents come in two different types.
Uncovered stents facilitate better embedding but can be difficult to remove and
have a high risk of dysphagia symptoms. The fully covered stents allow for easy
removal but have a higher risk of migration. The other most commonly used
products are self-expanding plastic stents. The advantages to these stents are
that they are easily retrieved endoscopically, but they have a higher migration
rate and are technically more difficult to place. </p>
<p> </p>
<p>A thorough history and physical examination of the patient
should be obtained. We recommend counseling patients about the possibility of
post procedure chest discomfort, which is due to the expansion of the stent for
up to seventy-two hours post deployment. </p>
<p> </p>
<p> </p>
<p> </p>
<p>We recommend a fluoroscopy compatible bed as well as C-arm
capabilities. A standard EGD scope is needed, as well as an easily accessible
pediatric scope. We recommend carbon dioxide insufflation as this is more
readily absorbed by the GI tract mucosa and is associated with less
postprocedure pain. The instructions for use card provided with the stent
should be carefully examined to ensure proper usage. We recommend general
anesthesia for this procedure as this facilitates easier placement, protects
the airway from possible aspiration, and allows for concurrent bronchoscopy if
needed. The patient should be positioned supine with the arms tucked to allow for
C-arm movement. The procedure should begin with a diagnostic EGD. Radio-opaque
markers are then used to note the GEJ, site of the lesion, and 2cm distal to
the lesion. A spring tip guidewire is then placed endoscopically and positioned
distal to the lesion. </p>
<p> </p>
<p>Choice of stent is guided by the internal diameter and
should be slightly larger than the lesion to provide adequate radial force. The
stent should overlap the lesion by 2cm proximally and distally. The EGD scope
is withdrawn, and the stent deployment apparatus is placed over the guidewire.
Proper placement is confirmed with fluoroscopy, and the stent is deployed
directly under fluoroscopy. We recommend avoidance of reinstrumentation after
deployment, which may dislodge the stent and lead to migration.</p><p><br></p><p></p><p>References</p>
<p><br>
[1] Fackche, N.T., Garner, M., Ito, T., Brock, M. (2020) Use of Esophageal Stents,
In Cameron, J.L., Cameron, A.M. (Eds), Current Surgical Therapy 13th ed. (pp.
70-78) 2020. Philadelphia: Elsevier Inc.</p>
<p><br>
[2]Wtodarczyk, J., Kuzdzal, J. Stenting in Palliation of Unresectable
Esophageal Cancer. World J Surg 2018; 42 (12): 3988-3996.</p>
<p><br>
[3] Rhee K., Kim J.H., Jung D.H., Han, J.W., Lee, Y.C., Shin S.K., et al.
Self-expandable metal stents for malignant esophageal obstruction: a
comparative study between extrinsic and intrinsic compression Dis Esophagus
2016; 29 (3): 224.</p>
<p><br>
[4] van Heel, N.C.M., Haringsma, J., Spaander, M.C.W., Bruno, M.J., Kuipers,
E.J., Short-Term Esophageal Stenting in the Management of Benign Perforations
Am J Gastroenterology 2010; 105 (7): 1515-1520.</p>
<p> </p>
<p>[5] Sharma, P., Kozarek R., Practice Parameters Committee of
the American College of Gastroenterology. Role of esophageal stents in benign
and malignant diseases Am J
Gastroenterol 2010; 105 (2) 258.</p>
<p><br>
[6] Fuccio, L., Hassan, C., Frazzoni, L., Miglio R., Repici, A. Clinical
outcomes following stent placement in refractory benign esophageal stricture: a
systematic review and meta-analysis. Endoscopy 2016; 48 (2): 141-148.</p>
<p> </p>
<p>[7] van Heel, N.C.M., Haringsma, J., Spaander, M.C.W.,
Didden, P., Bruno, M.J., Kuipers, E.J.,
Esophageal stents for palliation of malignant dysphagia and fistula recurrence
after esophagectomy. Gastrointest Endosc 2010; 72(2): 249.</p>
<p> </p>
<p>[8] Zhou, C., Hu, Y., Xiao, Y., Yin, W. Current treatment of
tracheoesophageal fistula. Ther Adv Respir Dis 2017; 11(4): 173</p><br><p></p>